Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
30.38
+0.06 (+0.20%)
Streaming Delayed Price
Updated: 1:17 PM EDT, Jul 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
713,608
Open
29.89
Bid (Size)
30.36 (1)
Ask (Size)
30.41 (4)
Prev. Close
30.32
Today's Range
29.21 - 30.97
52wk Range
16.95 - 49.50
Shares Outstanding
79,199,501
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Is Conn’s (CONN) Stock Down 36% Today?
Today 8:42 EDT
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Today 8:23 EDT
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock.
Via
InvestorPlace
Performance
YTD
+10.84%
+10.84%
1 Month
+22.35%
+22.35%
3 Month
+29.44%
+29.44%
6 Month
+21.52%
+21.52%
1 Year
-3.71%
-3.71%
More News
Read More
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
July 23, 2024
Via
Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
July 22, 2024
Via
InvestorPlace
Expert Ratings For Beam Therapeutics
April 23, 2024
Via
Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
March 27, 2024
Via
Benzinga
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
July 18, 2024
Via
Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
Via
InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Via
InvestorPlace
Exposures
Product Safety
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
July 03, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
June 27, 2024
Via
InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
Via
InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Via
Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
MarketBeat Week in Review – 3/4 – 3/8
March 09, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.